Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.

Bin CaoYeming WangHongzhou LuChaolin HuangYumei YangLianhan ShangZhu ChenRongmeng JiangYihe LiuLing LinPing PengFuxiang WangFengyun GongHonglin HuCong ChengXiangyang YaoXianwei YeHourong ZhouYinzhong ShenChenfan LiuChunying WangZhennan YiBijie HuJiuyang XuXiaoying GuJingshan ShenYechun XuLeike ZhangJia FanRenhong TangChen Wang

Published in: The New England journal of medicine (2024)

Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19, without evident safety concerns. (Funded by Jiangsu Simcere Pharmaceutical; ClinicalTrials.gov number, NCT05506176.).

Keyphrases

coronavirus disease
sars cov
single molecule
antiretroviral therapy
sleep quality
childhood cancer